Abstract
ABSTRACT Introduction Breast cancer is one of the leading causes of death in women worldwide. Although chemotherapy offers a good rate of response, the associated toxicity is a limiting factor for treatment. One of the current lines of research points to the Polyunsaturated Fatty Acids Omega-3 (PUFA O3) as one of the possibilities to enhance the antitumor effects of anthracyclines, with a consequent reduction in adverse effects. Aim Determine the additive or synergetic effect of PUFA-O3 on the cytotoxicity of doxorubicin in cell lines of breast cancer. Methodology We used the breast cancer cell line T47D to test the cytotoxic effect of docosahexaenoic acid (DHA) and doxorubicin (DOX) as single compounds and in combination at different concentrations and exposure periods. The proliferation was measured using Crystal Violet assay. All experiments were made by triplicate. Results are expressed as mean values + SD. Results Forty-eight hours after treatment with: DHA (70uM) cell proliferation decreased to 79.9 + 1.9%; DHA (100uM) 66 + 2.6%; DOX (0.1uM) 70.4 + 4.2%; and DOX (0.5uM) 51.6 + 2.2%. Seventy-two hours after treatment with: DHA (70uM) cell proliferation decreased to 69.7 + 6.3%; DHA (100uM) 42.9 + 1.0%; DOX (0.1uM) 50.9 + 9.7%; and DOX (0.5uM) 24.1 + 4.0%. Addition of DHA caused a reduction in the concentration of DOX required to reach the IC50. The concentration of DHA needed to reduce de IC50 of DOX from 0.5uM to 0.1 uM at 48 hs was 100uM; and from 0.1uM to 0.05uM at 72hrs was 70uM. Conclusion Our results confirmed cytotoxic activity of DHA, which has synergic effect when combined with DOX. Based on this, DHA could help to reach the therapeutic effect of DOX with lower doses, reducing the adverse effects. Disclosure All authors have declared no conflicts of interest.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call